Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) and keeping the price target at $66.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Whitney Ijem has given his Buy rating due to a combination of factors surrounding Arcturus Therapeutics’ recent developments. The company’s ARCT-810 program for OTC deficiency has shown promising safety and efficacy data, particularly with its novel liver-targeted LNP technology. The absence of serious adverse events and the positive biomarker results, such as stable ammonia levels and normalized glutamine levels, are encouraging signs of the therapeutic’s potential.
Furthermore, the ongoing developments in their cystic fibrosis program, ARCT-032, are anticipated to be significant value drivers. The upcoming data from this program, expected soon, could further bolster the company’s position. Despite some limitations in the current data set, such as small sample sizes and differing protocols, the overall outlook remains positive, supporting the Buy rating with a price target of $66.
According to TipRanks, Ijem is a 5-star analyst with an average return of 14.5% and a 48.87% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Verve Therapeutics, Vertex Pharmaceuticals, and Arcturus Therapeutics.